Chengdu Paile Biotechnology Co., Ltd. has completed a seed funding round exceeding ten million yuan, led by Xi'an Sanyuan Capital with participation from Wuhan Juhua Chuanxin Capital.
The proceeds from this round will be entirely directed toward the company's core pipeline, specifically the full-chain preclinical research of antivirulins targeting key clinical pathogenic bacteria, as well as team expansion.
According to public records, Paile Biotech was established in November 2024, co-founded by Dr. Zhao Kelei and Dr. Zhou Xikun. The core team members come from the Sichuan Industrial Institute of Antibiotics, the National Key Laboratory of Biotherapy at Sichuan University, and West China Hospital.
Rather than pursuing a "bactericidal" approach, the company focuses on "virulence control," targeting the bacterial quorum sensing (QS) system. By competitively binding to block the function of core regulatory proteins, it simultaneously inhibits toxin secretion, bacterial motility, drug efflux, and biofilm formation, rendering pathogenic bacteria harmless and restoring sensitivity to certain antibiotics that have already developed resistance.
The pipeline covers core strains listed in the World Health Organization's 2024 priority antimicrobial resistance bacterial catalog, spanning scenarios such as respiratory infections, burn and skin infections, tuberculosis, and urinary system infections.
The company has built its own high-throughput in vivo and in vitro efficacy evaluation system, as well as an integrated virtual screening platform called Dockey.
Comments